Although the mechanism is unclear, IDH1/2 mutations are thought to represent an early event in gliomagenesis and have been associated with a glioma-CpG island methylator phenotype (G-CIMP) and improved prognosis in glioblastoma [18], [22]–[24]. This evidence concerns the gene IDH1 and glioblastoma.